Changchun High-Tech gets green light for Fuxinqibaimab trial

Changchun High & New Technology Industry Group announced that its subsidiary, Changchun Jinsai Pharmaceutical, has received approval from the National Medical Products Administration for a clinical trial application for Fuxinqibaimab injection, a Class 1 biological drug for treatment. The drug will be tested for the treatment of endometriosis. Fuxinqibaimab injection is a novel drug developed by Jinsai Pharmaceutical, targeting the IL-1β receptor. A marketing application for the treatment of acute gouty arthritis was accepted by the regulators in January 2025. The company cautioned that the clinical trial process involves uncertainties and advised investors to exercise caution. The company (stock code SZSE:000661) will continue to disclose relevant information in a timely manner.